Bortezomib Accord 3.5 mg powder for solution for injection
Sponsors
Oslo University Hospital HF, Karyopharm Therapeutics Inc.
Conditions
Multiple myelomaPenta-refractory multiple myeloma and triple-class refractory multiple myeloma
Phase 2
A Phase 2b, Open-label, Multi-arm Clinical Trial of Selinexor Plus Low-dose Dexamethasone (Sd) in Patients with Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone (SVd) in Patients with Triple-class Refractory Multiple Myeloma
RecruitingCTIS2024-511608-18-00
Start: 2020-06-25Target: 55Updated: 2025-10-08
RElapse from Mrd Negativity As iNdication for Treatment
Active, not recruitingCTIS2023-510215-18-00
Start: 2024-09-26Target: 391Updated: 2025-11-07